<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973098</url>
  </required_header>
  <id_info>
    <org_study_id>CT0181-CG1202</org_study_id>
    <nct_id>NCT04973098</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-Label, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0181 Injection in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CARsgen Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives:&#xD;
&#xD;
      Evaluate the safety and tolerance of CT0181 cells in patients with advanced hepatocellular&#xD;
      carcinoma within 28 days after the first infusion&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Evaluate the metabolic kinetics of CT0181 cells ; Evaluate overall safety and tolerability ;&#xD;
      Evaluate the initial efficacy of CT0181 cell infusion in the treatment of advanced&#xD;
      hepatocellular carcinoma with positive Glypican-3（GPC3 ）expression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Dose-Limiting Toxicity（DLT）</measure>
    <time_frame>28days</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Tolerable Dose（MTD）</measure>
    <time_frame>28days</time_frame>
    <description>tolerability evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Event（TEAE）</measure>
    <time_frame>28days</time_frame>
    <description>Incidence rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event of Special Interest</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>5 dose levels each with or without lymphocyte clearance were tentatively determined.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT0181 Cells were transfused after lymphocyte clearance with fludarabine and cyclophosphamide or without lymphocyte clearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT0181 Cells</intervention_name>
    <description>5 dose levels each with or without lymphocyte clearance were tentatively determined.</description>
    <arm_group_label>5 dose levels each with or without lymphocyte clearance were tentatively determined.</arm_group_label>
    <other_name>CT0181 humanized anti GPC3 autogenous T Cell injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 75 years, either sex；&#xD;
&#xD;
          2. Patients with clinically or pathologically confirmed hepatocellular carcinoma were&#xD;
             treated with surgery or local treatment It is not suitable for surgery or local&#xD;
             radical treatment;&#xD;
&#xD;
          3. Progression or intolerance after at least one previous systemic treatment, or due to&#xD;
             specific reasons unable to receive systemic treatment.&#xD;
&#xD;
          4. According to Barcelona Clinic Liver Cancer（BCLC）, the patients are classified into&#xD;
             Grade C or Grade B unsuitable for local treatment/progressive disease after local&#xD;
             treatment;&#xD;
&#xD;
          5. In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC);&#xD;
&#xD;
          6. According to Response Evaluation Criteria in SolidTumors（RECIST1.1）,patients have at&#xD;
             least one evaluable target lesion;&#xD;
&#xD;
          7. Expected survival is &gt; 12 weeks;&#xD;
&#xD;
          8. Cirrhosis status Child-Pugh score: ≤7&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group Performance Status score: 0 to 1 point;&#xD;
&#xD;
         10. If the patient is HBsAg positive or HBcAb positive, DNA of the hepatitis B virus&#xD;
             should be &lt;2000 IU/ml. HBsAg positive patients must receive antiviral treatment ;&#xD;
&#xD;
         11. Acceptable routine blood test showing no contraindication to the lymphodepletion&#xD;
             pretreatment and adequate liver, renal, cardiovascular, respiratory function;&#xD;
&#xD;
         12. Have venous accesses for apheresis;&#xD;
&#xD;
         13. Subjects of childbearing age must undergo a serum pregnancy test . In addition, they&#xD;
             should be willing to use a reliable method of contraception during the trial (within&#xD;
             52 weeks after cell infusion); male subjects whose spouses are women of childbearing&#xD;
             age should undergo sterilization surgery or agree to use a reliable method of&#xD;
             contraception during the trial; Understand and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding women;&#xD;
&#xD;
          2. Hepatitis virus C antibodies ,Human Immunodeficiency Virus（HIV） antibodies or Syphilis&#xD;
             Serological tests are positive;&#xD;
&#xD;
          3. Any uncontrol active infection, including but not limited to active tuberculosis;&#xD;
&#xD;
          4. Have clinically significant thyroid dysfunction except the stable control after&#xD;
             treatment;&#xD;
&#xD;
          5. Previous or present hepatic encephalopathy;&#xD;
&#xD;
          6. Current clinically significant ascites;&#xD;
&#xD;
          7. Imaging results:≥50% of the liver is replaced by tumor or portal vein main tumor&#xD;
             thrombus, or metastases to the central nervous system, or tumor thrombus invasion of&#xD;
             mesenteric vein / inferior vena cava;&#xD;
&#xD;
          8. Subjects have known active autoimmune diseases&#xD;
&#xD;
          9. The side effects caused by the previous treatment of the subjects did not return to&#xD;
             Common Terminology Criteria for Adverse Events（CTCAE） ≤1; except hair loss and other&#xD;
             tolerable events determined by investigator;&#xD;
&#xD;
         10. Patients who had received systemic steroids or other immunosuppressive agents within 7&#xD;
             days before apheresis, except inhaled steroids;&#xD;
&#xD;
         11. History of severe allergy ;&#xD;
&#xD;
         12. Has signs of central nervous system disease or an abnormal neurological examination&#xD;
             with clinical significance;&#xD;
&#xD;
         13. Subjects with unstable or active ulcers, gastrointestinal bleeding, or pump inhibitor&#xD;
             intolerance;&#xD;
&#xD;
         14. Patients with a history of organ transplantation or waiting for organ transplantation;&#xD;
&#xD;
         15. Previously received Programmed cell Death-1/Programmed cell Death-Ligand 1 monoclonal&#xD;
             antibody therapy within 4 weeks or local treatment and systemic chemiotherapy within 2&#xD;
             weeks or immunotheray and molecular targeted drugs within 1 week before apheresis;&#xD;
&#xD;
         16. Previously received GPC3 targeted therapy;&#xD;
&#xD;
         17. Major surgery or significant trauma occurred within 4 weeks before apheresis, or it is&#xD;
             expected that major surgery needs to be performed during the trial;&#xD;
&#xD;
         18. Patients who had incurable malignant tumors in the past 5 years or at the same time,&#xD;
             except cervical cancer in situ and basal cell carcinoma of skin;&#xD;
&#xD;
         19. Other serious diseases that may restrict the subjects from participating in the trial&#xD;
             ；&#xD;
&#xD;
         20. The researcher assessed that the subjects were unable or unwilling to comply with the&#xD;
             requirements of the trial protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Changsong Qi</last_name>
    <phone>86-10-88196561</phone>
    <email>xiwangpku@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
      <phone>+86-13911219511</phone>
      <email>doctorshenlin@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Changsong Lin</last_name>
      <phone>+86-13811394004</phone>
      <email>xiwangpku@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Hepatocellular Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

